ScienceAlert on MSN
A Signal of Parkinson's May Be Hiding in Your Hair, Study Finds
Researchers in China have found a potential new biomarker of Parkinson's disease hiding in human hair. When the team analyzed ...
-Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept ("POC”) Study in Treatment Resistant Depression ("TRD”) in ...
In tissue samples collected from patients with prostate cancer, microplastics and nanoplastics (MNPs) were present in almost every one, according to a small proof-of-concept study. Among 10 patients ...
Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the ...
CYCN READ THE FULL CYCN RESEARCH REPORT Business Update Positive Regulatory Feedback Supports Phase 2 Trial Initiation in 2H26 On February 17, 2026, Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) ...
Mountain View, California Monday, February 16, 2026, 18:00 Hrs [IST] ...
The Phase 2 study is a multi-center, randomized, partially double-blind, placebo- and active-controlled trial designed to ...
Ketamine, a decades-old anesthetic and fast-acting treatment for severe depression, may also offer some people rapid relief ...
Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson’s disease, following completion of study ...
Data from Phase 2a study demonstrated the first clinical proof of concept for alpibectir in combination with ethionamide (AlpE) in the treatment ...
Seed&Spark Campaign Enters Final Two Weeks as Director and Casting Director Attachments Near. Film has the power to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results